Plain-English translation of NCT06793137 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a common and safe oral antibiotic, can help improve how well standard rectal cancer treatment works. Researchers believe that certain bacteria in your gut may interfere with radiation therapy, and by reducing those bacteria with the medication during the first week of treatment, they may be able to help more patients respond better to radiation and chemotherapy.
Some types of bacteria naturally living in your intestines appear to make rectal cancer treatments less effective. This study exists to see whether reducing those specific bacteria with this medication at the start of treatment can help more patients achieve better outcomes and potentially avoid surgery or preserve their rectum.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take by mouth (500 mg three times daily) for the first seven days while you start your standard radiation therapy. The research team will track how well you tolerate the medication, monitor you carefully for any side effects, and collect stool samples before and after treatment to study changes in your gut bacteria. You will continue your regular cancer treatment (radiation and chemotherapy) as planned, with follow-up visits to assess your response and overall health for up to three years.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Brazil